189 related articles for article (PubMed ID: 10774265)
1. Immunity to varicella zoster virus in young Israeli adults.
Avrahami-Heller Y; Cohen D; Orr N; Slepon R; Ashkenazi I; Danon YL
Isr Med Assoc J; 2000 Mar; 2(3):196-9. PubMed ID: 10774265
[TBL] [Abstract][Full Text] [Related]
2. Immunity to varicella zoster virus among young adults: a decline prior to widespread uptake of varicella vaccines.
Grotto I; Balicer RD; Smetana Z; Davidovitch N; Bar-Zeev Y; Mendelson E; Zarka S; Huerta M
Infection; 2008 Mar; 36(2):130-4. PubMed ID: 18379727
[TBL] [Abstract][Full Text] [Related]
3. Seroprevalence of Varicella-Zoster virus IgG antibodies in Swiss children during the first 16 months of age.
Heininger U; Desgrandchamps D; Schaad UB
Vaccine; 2006 Apr; 24(16):3258-60. PubMed ID: 16459000
[TBL] [Abstract][Full Text] [Related]
4. Seroprevalence of varicella-zoster virus in Polish population.
Siennicka J; Trzcińska A; Rosińska M; Litwińska B
Przegl Epidemiol; 2009; 63(4):495-9. PubMed ID: 20120946
[TBL] [Abstract][Full Text] [Related]
5. Loss of varicella zoster virus antibodies despite detectable cell mediated immunity after vaccination.
Ludwig B; Kraus FB; Allwinn R; Keim S; Doerr HW; Buxbaum S
Infection; 2006 Aug; 34(4):222-6. PubMed ID: 16896582
[TBL] [Abstract][Full Text] [Related]
6. Varicella-zoster virus immunity in dermatological patients on systemic immunosuppressant treatment.
Hackett CB; Wall D; Fitzgerald SF; Rogers S; Kirby B
Br J Dermatol; 2011 Jun; 164(6):1387-9. PubMed ID: 21410679
[TBL] [Abstract][Full Text] [Related]
7. [Varicella-zoster virus seroprevalence in children between 0-15 years old].
Savaş S; Dallar Y; Arikan I; Onde U
Mikrobiyol Bul; 2004; 38(1-2):69-75. PubMed ID: 15293904
[TBL] [Abstract][Full Text] [Related]
8. Restoration of varicella-zoster virus cell-mediated immune response after varicella booster vaccination.
Berger R; Luescher D; Just M
Postgrad Med J; 1985; 61 Suppl 4():143-5. PubMed ID: 3014472
[TBL] [Abstract][Full Text] [Related]
9. [Primary varicella-zoster virus infection--current knowledge, diagnostic and therapeutic approaches].
Cvjetković D; Jovanović J; Hrnjaković-Cvjetković I
Med Pregl; 2000; 53(5-6):272-6. PubMed ID: 11089369
[TBL] [Abstract][Full Text] [Related]
10. Seroepidemiology of varicella-zoster virus infection in a cosmopolitan city (Erzurum) in the eastern Turkey.
Alp H; Altinkaynak S; Ertekin V; Kiliçaslan B; Giiraksin A
Health Policy; 2005 Apr; 72(1):119-24. PubMed ID: 15760704
[TBL] [Abstract][Full Text] [Related]
11. Seroepidemiology of Varicella zoster in Israel prior to large-scale use of varicella vaccines.
Cohen DI; Davidovici BB; Smetana Z; Balicer RD; Klement E; Mendelson E; Green MS
Infection; 2006 Aug; 34(4):208-13. PubMed ID: 16896579
[TBL] [Abstract][Full Text] [Related]
12. The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection.
Hammond O; Wang Y; Green T; Antonello J; Kuhn R; Motley C; Stump P; Rich B; Chirmule N; Marchese RD
J Med Virol; 2006 Dec; 78(12):1679-87. PubMed ID: 17063506
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a two-dose regime of varicella vaccine in children with cancers.
Leung TF; Li CK; Hung EC; Chan PK; Mo CW; Wong RP; Chik KW
Eur J Haematol; 2004 May; 72(5):353-7. PubMed ID: 15059071
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of varicella-zoster antibodies in pregnant women in Catalonia (Spain). Rationale for varicella vaccination of women of childbearing age.
Plans P; Costa J; Espuñes J; Plasència A; Salleras L
BJOG; 2007 Sep; 114(9):1122-7. PubMed ID: 17666097
[TBL] [Abstract][Full Text] [Related]
15. Serological detection of specific IgG to varicella-zoster virus by novel ELISA based on viral glycoprotein antigen.
Sauerbrei A; Wutzler P
Clin Lab; 2009; 55(1-2):1-7. PubMed ID: 19350844
[TBL] [Abstract][Full Text] [Related]
16. Incidence of herpes zoster and seroprevalence of varicella-zoster virus in young adults of South Korea.
Kang CI; Choi CM; Park TS; Lee DJ; Oh MD; Choe KW
Int J Infect Dis; 2008 May; 12(3):245-7. PubMed ID: 17950022
[TBL] [Abstract][Full Text] [Related]
17. Low induction of varicella-zoster virus-specific secretory IgA antibody after vaccination.
Terada K; Niizuma T; Yagi Y; Miyashima H; Kataoka N; Sadahiro T
J Med Virol; 2000 Sep; 62(1):46-51. PubMed ID: 10935988
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of anti-varicella antibody in young women before their marriage: A sero-epidemiologic study in Iran.
Pourahmad M; Davami MH; Jahromi AR
J Clin Virol; 2010 Aug; 48(4):260-3. PubMed ID: 20538515
[TBL] [Abstract][Full Text] [Related]
19. Seroepidemiologic aspects of varicella zoster virus infections in an Israeli Jewish population.
Leventon-Kriss S; Yoffe R; Rannon L; Modan M
Isr J Med Sci; 1978 Jul; 14(7):766-70. PubMed ID: 210147
[TBL] [Abstract][Full Text] [Related]
20. Validity of reported varicella history as a marker for varicella zoster virus immunity among unvaccinated children, adolescents, and young adults in the post-vaccine licensure era.
Perella D; Fiks AG; Jumaan A; Robinson D; Gargiullo P; Pletcher J; Forke CM; Schmid DS; Renwick M; Mankodi F; Watson B; Spain CV
Pediatrics; 2009 May; 123(5):e820-8. PubMed ID: 19403475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
